BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9615713)

  • 1. Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209.
    Takeshita H; Kusuzaki K; Tsuji Y; Hirata M; Hashiguchi S; Nakamura S; Murata H; Ashihara T; Hirasawa Y
    Anticancer Res; 1998; 18(2A):739-42. PubMed ID: 9615713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
    Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
    Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line.
    Hirata M; Kusuzaki K; Takeshita H; Hashiguchi S; Hirasawa Y; Ashihara T
    Anticancer Res; 2001; 21(1A):317-20. PubMed ID: 11299755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the cytometric detection of doxorubicin resistance in osteosarcoma cells by determining cellular doxorubicin/DNA ratio.
    Takeshita H; Kusuzaki K; Murata H; Nakamura S; Ashihara T; Hirasawa Y
    Anticancer Res; 1999; 19(6B):5235-8. PubMed ID: 10697541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells.
    Breier A; Drobná Z; Barancík M
    Neoplasma; 1998; 45(4):248-53. PubMed ID: 9890669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
    Sebille S; Morjani H; Poullain MG; Manfait M
    Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
    Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
    J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene.
    Narasaki F; Oka M; Fukuda M; Nakano R; Ikeda K; Takatani H; Terashi K; Soda H; Yano O; Nakamura T; Doyle LA; Tsuruo T; Kohno S
    Cancer Chemother Pharmacol; 1997; 40(5):425-32. PubMed ID: 9272120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of duration of exposure to S9788, cyclosporin A or verapamil on sensitivity of multidrug resistant cells to vincristine or doxorubicin.
    Pérez V; Pierré A; Léonce S; Anstett M; Atassi G
    Anticancer Res; 1993; 13(4):985-90. PubMed ID: 8352569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo.
    Zhou Z; Wan L; Han Y; Meng X; Yang Q; Li Y; Yu Q; Shen Z; Guo C
    Pharm Biol; 2013 Aug; 51(8):968-73. PubMed ID: 23735077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Overcoming of multidrug resistance by a newly synthesized quinoline compound, MS-209].
    Naito M; Nakanishi O; Tsuruo T
    Nihon Rinsho; 1997 May; 55(5):1122-7. PubMed ID: 9155163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.
    Majumder S; Dutta P; Mukherjee P; Datta ER; Efferth T; Bhattacharya S; Choudhuri SK
    Cancer Lett; 2006 Nov; 244(1):16-23. PubMed ID: 16410038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.
    Choi CH; Kang G; Min YD
    Planta Med; 2003 Mar; 69(3):235-40. PubMed ID: 12677527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of multidrug resistance in a canine lymphoma cell line.
    Uozurmi K; Nakaichi M; Yamamoto Y; Une S; Taura Y
    Res Vet Sci; 2005 Jun; 78(3):217-24. PubMed ID: 15766940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
    Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
    Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel multidrug resistance reversal agents.
    Berger D; Citarella R; Dutia M; Greenberger L; Hallett W; Paul R; Powell D
    J Med Chem; 1999 Jun; 42(12):2145-61. PubMed ID: 10377220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.